Floatz logo

1,125 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
or502
Non-Small Cell Lung Carcinoma
OncoResponse, Inc.P1/2CC (40)
Pexmetinib
Non-Small Cell Lung Carcinoma
Dan ZandbergP1/2CC (40)
Pfl-721
Non-Small Cell Lung Carcinoma
Pierre Fabre MedicamentP1/2CC (40)
s241656
Non-Small Cell Lung Carcinoma
Institut de Recherches Internationales ServierP1/2CC (40)
sbt6290
Non-Small Cell Lung Carcinoma
Silverback TherapeuticsP1/2CC (40)
Selvigaltin
Non-Small Cell Lung Carcinoma
Galecto Biotech ABP1/2CC (40)
Silevertinib
Non-Small Cell Lung Carcinoma
Black Diamond Therapeutics, Inc.P1/2CC (40)
Spedox-6
Non-Small Cell Lung Carcinoma
University of California, IrvineP1/2CC (40)
S<Sup>3.15</Sup>,S<Sup>3.22</Sup>,S<Sup>3.29</Sup>-[(1,3,5-Triazinane-1,3,5-Triyl)Tris(3-Oxopropane-3,1-Diyl)]{N-[5-Oxo-5-({L-Valyl-N<Sup>5</Sup>-Carbamoyl-L-Ornithyl[(4-Aminophenyl)Methoxy]Carbonyl-N-Methyl-L-Valyl-Lvalyl-(3R,4S,5S)-3-Methoxy-5-Methyl-4-(Methylamino)Heptanoyl-(2R,3R)-N-[(1S,2R)-1-Hydroxy-1-Phenylpropan-2-Yl]-3-Methoxy-2-Methyl-3-[(2S)-Pyrrolidin-2-Yl]Propanamide}-N2.1-Yl)Pentanoyl]-?-Alanyldecakis(N-Methylglycyl)-L-Alanyl-N6-Carbamimidoyl-L-Lysyl-L-?-Aspartyl-L-Cysteinyl-(4R)-4-Hydroxy-L-Prolyl-L-Leucyl-L-Valyl-L-Asparaginyl-L-Prolyl-L-Leucyl-L-Cysteinyl-L-Leucyl-L-Histidyl-L-Prolyl-D-?-Aspartyl-L-Tryptophyl-N6-Carbamimidoyl-L-Lysyl-Lcysteinamide}
Non-Small Cell Lung Carcinoma
BicycleTx LimitedP1/2CC (40)
Stx-721
Non-Small Cell Lung Carcinoma
Pierre Fabre MedicamentP1/2CC (40)
SYS6090
Non-Small Cell Lung Carcinoma
Shanghai JMT-Bio Inc.P1/2CC (40)
Tovorafenib
Non-Small Cell Lung Carcinoma
Day One Biopharmaceuticals, Inc.P2CC (40)
tqb3728
Non-Small Cell Lung Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P1/2CC (40)
tt125-802
Non-Small Cell Lung Carcinoma
TOLREMO therapeutics AGP1CC (40)
Tub-040
Non-Small Cell Lung Carcinoma
Tubulis GmbHP1/2CC (40)
Tuvusertib
Non-Small Cell Lung Carcinoma
EMD Serono Research & Development Institute, Inc.P1/2CC (40)
Valemetostat
Non-Small Cell Lung Carcinoma
Daiichi SankyoP1/2CC (40)
Vic-1911
Non-Small Cell Lung Carcinoma
Vitrac Therapeutics, LLCP1CC (40)
xnw5004
Non-Small Cell Lung Carcinoma
Evopoint Biosciences Inc.P1/2CC (40)
XYA02
Non-Small Cell Lung Carcinoma
XYone Therapeutics, IncP1/2CC (40)
zg005
Non-Small Cell Lung Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,LtdP1/2CC (40)
[177lu]lu-akir001
Non-Small Cell Lung Carcinoma
Karolinska University HospitalEarly P1C (39)
1H-Isoindol-1-one, 2,3-dihydro-2-[3-[cis-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[(3S)-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-
Non-Small Cell Lung Carcinoma
Nurix Therapeutics, Inc.P1C (39)
68ga-dfc413
Non-Small Cell Lung Carcinoma
Novartis PharmaceuticalsP1C (39)
ab598
Non-Small Cell Lung Carcinoma
Arcus Biosciences, Inc.P1C (39)
Abequolixron
Non-Small Cell Lung Carcinoma
UNC Lineberger Comprehensive Cancer CenterP1C (39)
azd0022
Non-Small Cell Lung Carcinoma
AstraZenecaP1C (39)
bay2862789
Non-Small Cell Lung Carcinoma
BayerP1C (39)
bi 765063
Non-Small Cell Lung Carcinoma
Boehringer IngelheimP1C (39)
bi 770371
Non-Small Cell Lung Carcinoma
Boehringer IngelheimP1C (39)
Bms-986463
Non-Small Cell Lung Carcinoma
Bristol-Myers SquibbP1C (39)
Cdx-585
Non-Small Cell Lung Carcinoma
Celldex TherapeuticsP1C (39)
Eli-002 7P
Non-Small Cell Lung Carcinoma
Elicio TherapeuticsP1C (39)
exs74539
Non-Small Cell Lung Carcinoma
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.P1C (39)
Gamma4 Heavy Chain Homo Sapiens (1-446) [Vh (Homo Sapiens Ighv4-39*01 (96.0%) -(Ighd) -Ighj3*02 (100%), Cdr-Imgt [10.7.12] (26-35.53-59.98-109)) (1-120)-Homo Sapiens Ighg4*01, Ng4M(A) Ch2 L92, G4V5 H P10, G4V4 Ch2 A1.3, A1.2 (Ch1 (121-218), Hinge 1-12 S10>P (228) (219-230), Ch2 F1.3>A (234), L1.2>A (235), L92 (309) (231-340), Ch3 (341-445), Chs K2>Del (446)) (121-446)], (134-215')-Disulfide With Kappa Light Chain Homo Sapiens (1'-215') [V-Kappa (Homo Sapiens Igkv1-33*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt[6.3.10] (27'-32'.50'-52'.89'-98')) (1'-108') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (154'), V101 (192') (109'-215')], Dimer (226-226'':229-229'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho)-K1Sv Cell Line Lacking The Glutamine Synthetase Gene (Gs-Ko), Glycoform Alfa
Non-Small Cell Lung Carcinoma
Innovent Biologics (Suzhou) Co. Ltd.P1C (39)
ide574
Non-Small Cell Lung Carcinoma
IDEAYA BiosciencesP1C (39)
kj015
Non-Small Cell Lung Carcinoma
Shanghai Bao Pharmaceuticals Co., Ltd.P1C (39)
Kras-Specific Autologous Tcr-T Cell
Non-Small Cell Lung Carcinoma
Corregene Biotechnology Co., LtdP1C (39)
lt-010391
Non-Small Cell Lung Carcinoma
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.P1C (39)
Migoprotafib
Non-Small Cell Lung Carcinoma
Genentech, Inc.P1C (39)
pf-07224826
Non-Small Cell Lung Carcinoma
PfizerP1C (39)
pf-07257876
Non-Small Cell Lung Carcinoma
PfizerP1C (39)
prt2527
Non-Small Cell Lung Carcinoma
Prelude TherapeuticsP1C (39)
rad301
Non-Small Cell Lung Carcinoma
Radiopharm Theranostics, LtdP1C (39)
Rmc-5127
Non-Small Cell Lung Carcinoma
Revolution Medicines, Inc.P1C (39)
ro7496353
Non-Small Cell Lung Carcinoma
Genentech, Inc.P1C (39)
Smet12
Non-Small Cell Lung Carcinoma
Fujian Cancer HospitalEarly P1C (39)
Microlyvaq™
Non-Small Cell Lung Carcinoma
Biogenea Pharmaceuticals Ltd.Early P1C (38)
Sasanlimab
Non-Small Cell Lung Carcinoma
PfizerP2/3C (38)
18f-αvβ6-bp
Non-Small Cell Lung Carcinoma
University of California, DavisP1C (37)
Showing 801 to 850 of 1,125 assets
PreviousPage 17 of 23Next